What You Should Know:
– Patient-centered health data company PicnicHealth today announced it has acquired AllStripes, a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. Financial terms of the transaction are not disclosed.
– Founded in 2017, AllStripes has developed a technology platform that generates research-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data.
Harness the Power of Patient Data to Support Biomedical Research
PicnicHealth engages directly with patients to collect and curate comprehensive clinical data and patient-reported outcomes (PROs) to generate rich insights across patient healthcare journeys. Historically, generating such evidence has required the establishment of a network of clinical sites, which are expensive to operate, burdensome to patients and sites, and often lead to delays. PicnicHealth and AllStripes pioneered a new model by working directly with patients, which enables a deeper view of each patient’s health and experience while reducing the challenges of traditional site-based studies. With AllStripes’ strong relationships across patient communities, PicnicHealth expands its footprint and enhances its ability to guide critical and deep evidence generation.
This acquisition will enable PicnicHealth to curate rich clinical data sets and patient-reported outcomes data to enhance offerings across a broader range of diseases and better serve diverse biopharma customers’ evidence-generation needs, including both clinical research and registry development.
“Through this acquisition, PicnicHealth will be able to better engage our patient community by incorporating the best of AllStripes’ patient experience into the PicnicHealth platform,” said Noga Leviner, CEO of PicnicHealth. “AllStripes and PicnicHealth share a common vision of elevating clinical studies by putting patients at the core of the research experience. By combining forces, we can unlock the potential of patient-centered studies and provide best-in-class solutions to support therapeutic development.”
